Facebook Twitter LinkedIn Google Plus RSS

Actavis confirms generic Diprivan patent challenge

By ,

Parsippany-based Actavis Inc. on Friday said it filed an abbreviated new-drug application with the U.S. Food and Drug Administration seeking approval to market a generic version of Fresenius Kabi's Diprivan, an intravenously administered sedative and anesthetic.

According to the announcement, Fresenius Kabi USA LLC filed suit against Actavis on June 6 in a bid to prevent Actavis from commercializing its generic product prior to the expiration of certain U.S. patents.

For the 12 months ending April 30, brand and generic versions of Diprivan had total U.S. sales of approximately $212 million, according to IMS Health data cited by Actavis in its announcement.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy